CLAIMS

1. A composition comprising mesenchymal lineage precursor or stem cells in which the mesenchymal lineage precursor or stem cells are cryopreserved and, after thawing, inhibit proliferation of activated T cells in a sample of PBMC by at least about 65%.

2. A composition according to Claim 1, in which the inhibition of proliferation of activated T cells is measured by inhibition of IL-2R 2Rα expression in the activated T cells.

3. A composition according to Claim 1 or 2, in which co-incubation of mesenchymal lineage precursor or stem cells with PMBC at a ratio of 1 mesenchymal lineage precursor or stem cell:5 PMBC, or less, inhibits T cell proliferation by at least about 65%.

4. A composition according to Claim 1 or 2, in which co-incubation of mesenchymal lineage precursor or stem cells with PMBC at a ratio of 1 mesenchymal lineage precursor or stem cell:10 PMBC, or less, inhibits T cell proliferation by at least about 65%.

5. A composition according to Claim 1 or 2, in which co-incubation of mesenchymal lineage precursor or stem cells with PMBC at a ratio of 1 mesenchymal lineage precursor stem cell:50 PMBC, or less, inhibits T cell proliferation by at least about 65%.

6. A composition according to Claim 1 or 2, in which co-incubation of mesenchymal lineage stem cells with PBMC at a ratio of 1 mesenchymal lineage precursor or stem cell:100 PBMC, or less, inhibits T cell proliferation by at least about 65%.

7. A composition according to any preceding claim, in which co-incubation of mesenchymal lineage precursor or stem cells with PMBC at a ratio of 1 mesenchymal lineage precursor or stem cell:5 PMBC, or less, inhibits T cell proliferation by at least about 70%.

8. A composition according to any preceding claim, in which co-incubation of mesenchymal lineage precursor or stem cells with PMBC at a ratio of 1 mesenchymal lineage precursor or stem cell:5 PMBC, or less, inhibits T cell proliferation by at least about 80%.

9. A composition according to any preceding claim, in which the mesenchymal lineage precursor or stem cells express TNFR1 in an amount of at least 270 pg/ml.

10. A composition according to any of Claims 1 to 8, in which the mesenchymal lineage precursor or stem cells express TNFR1 in an amount of at least 300 pg/ml.

11. A composition according to any of Claims 1 to 8, in which the mesenchymal lineage precursor or stem cells express TNFR1 in an amount of at least 320 pg/ml.

12. A composition according to any preceding claim, in which the mesenchymal lineage precursor or stem cells are isolated by immunoselection.

13. A composition according to any preceding claim, in which the mesenchymal lineage precursor or stem cells are culture expanded mesenchymal stem cells.

14. Use of a composition comprising mesenchymal lineage precursor or stem cells according to any preceding claim in the manufacture of a medicament for treating an inflammatory disorder in a subject in need thereof.

15. Use according to Claim 14, in which the inflammatory disorder is a T-cell mediated inflammatory disorder.

16. Use of a composition comprising mesenchymal lineage precursor or stem cells according to any of Claims 1 to 13 in the manufacture of a medicament for preventing, alleviating the development of, or treating graft versus host disease (GVHD) in a subject.

17. Use according to any of Claims 14 to 16, in which the composition comprises a dose of less than 3×10^6 cells/kg.

18. Use according to any of Claims 14 to 17, in which the composition comprises a dose of about 2×10^6 cells/kg.

19. Use according to any of Claims 14 to 18 in which the composition comprises 2×10^6 cells/kg.

20. Use of mesenchymal lineage precursor or stem cells (MLPSCs) and/or progeny cells thereof in the manufacture of a medicament for preventing, alleviating the development of, or treating graft versus host disease (GVHD) in a mammalian subject.

21. Use according to Claim 20, in which the composition comprises about 2×10^6 cells/kg.

22. Use according to any of Claims 14 to 21, in which the subject is a pediatric human subject.

23. Use according to any of Claims 14 to 22, in which the subject has a malignant or genetic disorder of the blood.

24. Use according to any of Claims 14 to 23, in which the subject has received, is receiving or is about to receive a donor graft comprising hematopoietic cells.

25. Use according to Claim 24, in which the graft comprises hematopoietic stem cells (HSCs).

26. Use according to Claim 24 or 25, in which the graft comprises allogeneic hematopoietic cells.

27. Use according to any of Claims 14 to 26, in which the MLPSCs are mesenchymal precursor cells (MPCs).

28. Use according to any of Claims 14 to 27, in which the subject has acute GVHD.